Clinical Trials
15 trialsNCT05256225 2026-05-27
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07198074 2026-05-27
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06952504 2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06340568 2026-05-20
Fern-EC-01
BioNTech SE
Phase 3 Recruiting
NCT07044336 2026-05-20
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT07166094 2026-05-06
RAINFOL-03
Genmab
Phase 3 Recruiting
NCT05611931 2026-04-23
XPORT-EC-042
Karyopharm Therapeutics Inc
Phase 3 Recruiting
NCT03785288 2026-04-22
Vaginal Cuff Brachytherapy Fractionation Study
University of Virginia
Phase 3 Recruiting
NCT04789694 2026-03-19
PHOCUS
Charles University, Czech Republic
Phase 3 Recruiting
NCT07022483 2026-02-04
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT04073706 2026-01-30
ENDO-3
Queensland Centre for Gynaecological Cancer
Phase 3 Recruiting
NCT06712472 2026-01-20
RAINBO-RED
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting